Ambeed.cn

首页 / 抑制剂/激动剂 / 膜转运蛋白 / CFTR / PPQ-102

PPQ-102 {[allProObj[0].p_purity_real_show]}

货号:A621408 同义名: CFTR Inhibitor; Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor IV

PPQ-102是一种强效、独立于电压的 CFTR 抑制剂,可完全抑制 CFTR 氯离子电流,IC50 约为 90 nM,可有效防止多囊肾病囊肿扩大。

PPQ-102 化学结构 CAS号:931706-15-9
PPQ-102 化学结构
CAS号:931706-15-9
PPQ-102 3D分子结构
CAS号:931706-15-9
PPQ-102 化学结构 CAS号:931706-15-9
PPQ-102 3D分子结构 CAS号:931706-15-9
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

PPQ-102 纯度/质量文件 产品仅供科研

货号:A621408 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025, 188, (21): 5847-5861.e11. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025, 20, 1502-1513. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 CFTR 其他靶点 纯度
Ataluren 98%
Lumacaftor ++++

F508del-CFTR, EC50: 0.1 μM

98%
CFTR(inh)-172 +++

CFTR, Ki: 300 nM

99%+
GlyH-101 +

CFTR, Ki: 4.3 μM

99%+
IOWH-032 ++

CFTR, IC50: 1.01 μM

99%+
Tezacaftor 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

PPQ-102 生物活性

描述 CFTR is a chloride channel, that controls ion and water secretion and absorption in epithelial tissues. CFTR protein dysfunction leads to abnormal ion transport across the airway epithelium[3]. PPQ2 as a small molecule CFTR inhibitor that completely inhibited CFRR chloride current with IC50 value of 90 nM[4]. In vitro, PPQ-102 at the dose of 10µM inhibited CFTR almost 100% in (nonpermeabilized) human intestinal (T84) and bronchial cells following maximal CFTR activation by forskolin and IBMX. However, PPQ-102 did not inhibit calcium-activated chloride channels or cellular cAMP production[4]. PPQ-102 also inhibited the volume-regulated anion channel (VRAC) conductance with IC50 value of 20μM in HEK293 cells[5]. Treatment of NCI-H292 cells with 10μM PPQ-102 induced a two-fold increase in VEGF-A synthesis[3]. In the presence of NADPH, PPQ-102 lost in hepatic microsomes about 60% within 30min. No loss of PPQ-102 was seen in the absence of NADPH. In vivo, PPQ-102 was undetectable in serum, kidney and urine at 30-60 min after intravenous administration of 300μg PPQ-102 by LC/MS assay with sensitivity better than 100nM[6].
作用机制 PPQ-102 inhibits CFTR by an altered channel gating mechanism, with stabilization of the channel closed state[4].

PPQ-102 细胞实验

Cell Line
Concentration Treated Time Description References
NPTr cells 30 µM 2 hours Inhibition of VRAC activity, reducing CDT-induced apoptosis in NPTr cells Virulence. 2023 Dec;14(1):2287339
CFBE41o- WT cells 0.1, 1, 5, 10, 20, 30 µM 48 hours To evaluate the anti-SARS-CoV-2 activity of PPQ-102. Results showed that PPQ-102 inhibited SARS-CoV-2 replication by nearly 100% at 30 μM, with an IC50 of 15.92 μM. Cells. 2023 Feb 28;12(5):776
HEK-293 cells 10 µM and 30 µM 5 minutes Test the inhibitory effect of PPQ-102 on VRAC/LRRC8-mediated chloride conductance, with an IC50 value of 19.6±1.5 μM Front Pharmacol. 2017 May 31;8:328

PPQ-102 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Mice Polycystic kidney disease model Added to culture medium 0.5 µM, 2.5 µM, 5 µM Medium replaced every 12 hours for 4 days Evaluating PPQ-102 inhibition of cyst formation, 0.5 μM PPQ-102 inhibited cyst formation by ~60%, and 2.5 μM and 5 μM PPQ-102 nearly completely inhibited cyst formation. J Med Chem. 2009 Oct 22;52(20):6447-55

PPQ-102 参考文献

[1]Martin C, Coolen N, et al. CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. Eur Respir J. 2013 Dec;42(6):1553-62.

[2]Tradtrantip L, Sonawane ND,et al. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem. 2009 Oct 22;52(20):6447-55.

[3]Martin C, Coolen N, Wu Y, Thévenot G, Touqui L, Prulière-Escabasse V, Papon JF, Coste A, Escudier E, Dusser DJ, Fajac I, Burgel PR. CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. Eur Respir J. 2013 Dec;42(6):1553-62

[4]Tradtrantip L, Sonawane ND, Namkung W, Verkman AS. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem. 2009 Oct 22;52(20):6447-55

[5] Friard J, Tauc M, Cougnon M, Compan V, Duranton C, Rubera I. Comparative Effects of Chloride Channel Inhibitors on LRRC8/VRAC-Mediated Chloride Conductance. Front Pharmacol. 2017 May 31;8:328

[6] Snyder DS, Tradtrantip L, Yao C, Kurth MJ, Verkman AS. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem. 2011 Aug 11;54(15):5468-77

PPQ-102 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.40mL

2.28mL

1.14mL

22.81mL

4.56mL

2.28mL

PPQ-102 技术信息

CAS号931706-15-9
分子式C26H22N4O3
分子量 438.48
SMILES Code CC1=CC=C(C2C3=C(C4=C(N3C5=C(N2)C=CC=C5)C6=CC=CC=C6)N(C)C(N(C4=O)C)=O)O1
MDL No. MFCD14824240
别名 CFTR Inhibitor; Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor IV; CFTR Inhibitor IV
运输蓝冰
InChI Key MNOOVRNGPIWJDI-UHFFFAOYSA-N
Pubchem ID 16016583
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

DMSO: 50 mg/mL(114.03 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。